Search

Your search keyword '"Gates-Hollingsworth, Marcellene"' showing total 33 results
Start Over Author "Gates-Hollingsworth, Marcellene"
33 results on '"Gates-Hollingsworth, Marcellene"'

1. Electrochemical Immunoassay for Capturing Capsular Polysaccharide of Burkholderia pseudomallei: Early Onsite Detection of Melioidosis

Author

Madhurantakam, Sasya, primary, Karnam, Jayanth Babu, additional, Dhamu, Vikram Narayanan, additional, Seetaraman, Santosh, additional, Gates- Hollingsworth, Marcellene A., additional, AuCoin, David P., additional, Clark, Danielle V., additional, Schully, Kevin L., additional, Muthukumar, Sriram, additional, and Prasad, Shalini, additional

Published
2024
Full Text
View/download PDF

3. Serum antibody levels to SARS-CoV-2 receptor-binding domain (RBD) in convalescent patients and vaccinated individuals of northern Nevada

Author

Hau, Derrick, primary, Pflughoeft, Kathryn J., additional, Gates-Hollingsworth, Marcellene A., additional, Kaur, Simranjit, additional, Hill, Haydon J., additional, Arias-Umana, Jose, additional, Chung, Chelsea C., additional, Smith, Valerie L., additional, Riddle, Mark S., additional, Healy, Sara A., additional, and AuCoin, David P., additional

Published
2023
Full Text
View/download PDF

4. Functional assays to screen and select monoclonal antibodies that target Yersinia pestis

Author

Biryukov, Sergei S., primary, Rill, Nathaniel O., additional, Klimko, Christopher P., additional, Dankmeyer, Jennifer L., additional, Shoe, Jennifer L., additional, Hunter, Melissa, additional, Talyansky, Yuli, additional, Hau, Derrick, additional, Gates-Hollingsworth, Marcellene A., additional, Pandit, Sujata G., additional, Fetterer, David P., additional, Qiu, Ju, additional, Davies, Michael L., additional, AuCoin, David P., additional, and Cote, Christopher K., additional

Published
2023
Full Text
View/download PDF

5. Sharp Branched Gold Nanostar-Based Lateral-Flow Immunoassay for Detection of Yersinia pestis

Author

Atta, Supriya, primary, Canning, Aidan J., additional, Odion, Ren, additional, Wang, Hsin-neng, additional, Hau, Derrick, additional, Devadhasan, Jasmine Pramila, additional, Summers, Alexander Jarrett, additional, Gates-Hollingsworth, Marcellene A., additional, Pflughoeft, Kathryn J., additional, Gu, Jian, additional, Montgomery, Douglas C., additional, AuCoin, David P., additional, Zenhausern, Frederic, additional, and Vo-Dinh, Tuan, additional

Published
2023
Full Text
View/download PDF

6. Comparison of a Prototype SARS-CoV-2 Lateral Flow IMMUNOASSAY with the BinaxNOWTM COVID-19 Antigen CARD

Author

Hill, Haydon J., primary, Uppal, Timsy, additional, Hau, Derrick, additional, Pandit, Sujata G., additional, Arias-Umana, Jose, additional, Foster, Abigail J., additional, Gorzalski, Andrew, additional, Pflughoeft, Kathryn J., additional, Burnham-Marusich, Amanda R., additional, Reed, Dana E., additional, Gates-Hollingsworth, Marcellene A., additional, Gumbleton, Lynette, additional, Verma, Subhash C., additional, and AuCoin, David P., additional

Published
2022
Full Text
View/download PDF

7. Functional assays to screen and select monoclonal antibodies that target Yersinia pestis

Author

Biryukov, Sergei S., Rill, Nathaniel O., Klimko, Christopher P., Dankmeyer, Jennifer L., Shoe, Jennifer L., Hunter, Melissa, Talyansky, Yuli, Hau, Derrick, Gates-Hollingsworth, Marcellene A., Pandit, Sujata G., Fetterer, David P., Qiu, Ju, Davies, Michael L., AuCoin, David P., and Cote, Christopher K.

Abstract

Yersinia pestis is a gram-negative bacterium that causes plague in animals and humans. Depending on the route of disease transmission, the bacterium can cause an acute, often fatal disease that has a narrow window for treatment with antibiotics. Additionally, antibiotic resistant strains have been identified, emphasizing the need for novel treatments. Antibody therapy is an appealing option that can direct the immune system to clear bacterial infections. Advances in biotechnology have made both engineering and producing antibodies easier and more affordable. In this study, two screening assays were optimized to evaluate the ability of antibodies to promote phagocytosis of Y. pestis by macrophages and to induce a cytokine signature in vitro that may be predictive of protection in vivo. We evaluated a panel of 21 mouse monoclonal antibodies targeting either the anti-phagocytic capsule F1 protein or the LcrV antigen, which is part of the type 3 secretion system that facilitates translocation of virulence factors into the host cell, using two functional assays. Anti-F1 and anti-LcrV monoclonal antibodies both increased bacterial uptake by macrophages, with greater uptake observed in the presence of antibodies that were protective in the mouse pneumonic plague model. In addition, the protective anti-F1 and anti-LcrV antibodies produced unique cytokine signatures that were also associated with in vivo protection. These antibody-dependent characteristics from in vitro functional assays will be useful in down-selecting efficacious novel antibodies that can be used for treatment of plague.

Published
2023
Full Text
View/download PDF

8. Detection and Quantification of the Capsular Polysaccharide of Burkholderia pseudomallei in Serum and Urine Samples from Melioidosis Patients

Author

DeMers, Haley L., primary, Nualnoi, Teerapat, additional, Thorkildson, Peter, additional, Hau, Derrick, additional, Hannah, Emily E., additional, Green, Heather R., additional, Pandit, Sujata G., additional, Gates-Hollingsworth, Marcellene A., additional, Boutthasavong, Latsaniphone, additional, Luangraj, Manophab, additional, Woods, Kate L., additional, Dance, David, additional, and AuCoin, David P., additional

Published
2022
Full Text
View/download PDF

10. Accuracy of 2 Rapid Antigen Tests During 3 Phases of SARS-CoV-2 Variants

Author

Drain, Paul K., primary, Bemer, Meagan, additional, Morton, Jennifer F., additional, Dalmat, Ronit, additional, Abdille, Hussein, additional, Thomas, Katherine K., additional, Uppal, Timsy K., additional, Hau, Derrick, additional, Green, Heather R., additional, Gates-Hollingsworth, Marcellene A., additional, AuCoin, David P., additional, and Verma, Subhash C., additional

Published
2022
Full Text
View/download PDF

14. Development of a dual antigen lateral flow immunoassay for detecting Yersinia pestis

Author

Hau, Derrick, primary, Wade, Brian, additional, Lovejoy, Chris, additional, Pandit, Sujata G., additional, Reed, Dana E., additional, DeMers, Haley L., additional, Green, Heather R., additional, Hannah, Emily E., additional, McLarty, Megan E., additional, Creek, Cameron J., additional, Chokapirat, Chonnikarn, additional, Arias-Umana, Jose, additional, Cecchini, Garett F., additional, Nualnoi, Teerapat, additional, Gates-Hollingsworth, Marcellene A., additional, Thorkildson, Peter N., additional, Pflughoeft, Kathryn J., additional, and AuCoin, David P., additional

Published
2022
Full Text
View/download PDF

15. Comparison of a Prototype SARS-CoV-2 Lateral Flow IMMUNOASSAY with the BinaxNOW TM COVID-19 Antigen CARD.

Author

Hill, Haydon J., Uppal, Timsy, Hau, Derrick, Pandit, Sujata G., Arias-Umana, Jose, Foster, Abigail J., Gorzalski, Andrew, Pflughoeft, Kathryn J., Burnham-Marusich, Amanda R., Reed, Dana E., Gates-Hollingsworth, Marcellene A., Gumbleton, Lynette, Verma, Subhash C., and AuCoin, David P.

Subjects
SARS-CoV-2, IMMUNOASSAY, SARS disease, COVID-19
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the virus responsible for the COVID-19 pandemic. From the onset of the pandemic, rapid antigen tests have quickly proved themselves to be an accurate and accessible diagnostic platform. The initial (and still most commonly used antigen tests) for COVID-19 diagnosis were constructed using monoclonal antibodies (mAbs) specific to severe acute respiratory syndrome coronavirus (SARS-CoV) nucleocapsid protein (NP). These mAbs are able to bind SARS-CoV-2 NP due to high homology between the two viruses. However, since first being identified in 2019, SARS-CoV-2 has continuously mutated, and a multitude of variants have appeared. These mutations have an elevated risk of leading to possible diagnostic escape when using tests produced with SARS-CoV-derived mAbs. Here, we established a library of 18 mAbs specific to SARS-CoV-2 NP and used two of these mAbs (1CV7 and 1CV14) to generate a prototype antigen-detection lateral flow immunoassay (LFI). A side-by-side analysis of the 1CV7/1CV14 LFI and the commercially available BinaxNOWTM COVID-19 Antigen CARD was performed. Results indicated the 1CV7/1CV14 LFI outperformed the BinaxNOWTM test in the detection of BA.2, BA.2.12.1, and BA.5 Omicron sub-variants when testing remnant RT-PCR positive patient nasopharyngeal swabs diluted in viral transport media. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

16. Point-of-Care Vertical Flow Immunoassay System for Ultra-Sensitive Multiplex Biothreat-Agent Detection in Biological Fluids

Author

Devadhasan, Jasmine Pramila, primary, Summers, Alexander Jarrett, additional, Gu, Jian, additional, Smith, Stanley, additional, Thomas, Baiju, additional, Fattahi, Ali, additional, Helton, James, additional, Pandit, Sujata G., additional, Gates-Hollingsworth, Marcellene, additional, Hau, Derrick, additional, Pflughoeft, Kathryn J., additional, Montgomery, Douglas C., additional, Atta, Supriya, additional, Vo-Dinh, Tuan, additional, AuCoin, David, additional, and Zenhausern, Frederic, additional

Published
2022
Full Text
View/download PDF

17. Development of Immunoassays for Detection of Francisella tularensis Lipopolysaccharide in Tularemia Patient Samples

Author

Hannah, Emily E., primary, Pandit, Sujata G., additional, Hau, Derrick, additional, DeMers, Haley L., additional, Robichaux, Kayleigh, additional, Nualnoi, Teerapat, additional, Dissanayaka, Anjana, additional, Arias-Umana, Jose, additional, Green, Heather R., additional, Thorkildson, Peter, additional, Pflughoeft, Kathryn J., additional, Gates-Hollingsworth, Marcellene A., additional, Ozsurekci, Yasemin, additional, and AuCoin, David P., additional

Published
2021
Full Text
View/download PDF

19. Digital image analysis for biothreat detection viarapid centrifugal microfluidic orthogonal flow immunocapture

Author

Woolf, M. Shane, Dignan, Leah M., Karas, Scott M., Lewis, Hannah M., Kim, Sabrina N., Geise, Geoffrey M., DeMers, Haley L., Hau, Derrick, Gates-Hollingsworth, Marcellene A., AuCoin, David P., and Landers, James P.

Abstract

We report clear proof-of-principle for centrifugally-driven, multiplexed, paper-based orthogonal flow sandwich-style immunocapture (cOFI) and colorimetric detection of Zaire Ebola virus-like particles. Capture antibodies are immobilized onto nanoporous nitrocellulose membranes that are then laminated into polymeric microfluidic discs to yield ready-to-use analytical devices. Fluid flow is controlled solely by rotational speed, obviating the need for complex pneumatic pumping systems, and providing more precise flow control than with the capillary-driven flow used in traditional lateral flow immunoassays (LFIs). Samples containing the antigen of interest and gold nanoparticle-labeled detection antibodies are pumped centrifugally through the embedded, prefunctionalized membrane where they are subsequently captured to generate a positive, colorimetric signal. When compared to the equivalent LFI counterparts, this cOFI approach generated immunochromatographic colorimetric responses that are objectively darker (saturation), more intense (grayscale), and less variable regarding total area of the color response. We also describe an image analysis approach that enables access to rich color data and area statistics without the need for a commercial ‘strip reader’ or custom-written image analysis algorithms. Instead, our analytical method exploits inexpensive equipment (e.g., smart phone, flatbed scanner, etc.) and freely available software (Fiji distribution of ImageJ) to permit characterization of immunochromatographic responses that includes multiple color metrics, offering insights beyond typical grayscale analysis. The findings reported here stand as clear proof-of-principle for the feasibility of disc-based, centrifugally driven orthogonal flow through a membrane with immunocapture (cOFI) and colorimetric readout of a sandwich-type immunoassay in less than 15 minutes. Once fully developed, this cOFI platform could render a faster, more accurate diagnosis, while processing multiple samples simul-taneously.

Published
2023
Full Text
View/download PDF

20. Characterization of a Centrifugal Microfluidic Orthogonal Flow Platform.

Author

Woolf, Michael Shane, Dignan, Leah M., Karas, Scott M., Lewis, Hannah M., Hadley, Kevyn C., Nauman, Aeren Q., Gates-Hollingsworth, Marcellene A., AuCoin, David P., Green, Heather R., Geise, Geoffrey M., and Landers, James P.

Subjects
ENZYME-linked immunosorbent assay, DRAINAGE, PNEUMATICS, AIR pumps, FLUID flow, BOND prices
Abstract

To bring to bear the power of centrifugal microfluidics on vertical flow immunoassays, control of flow orthogonally through nanoporous membranes is essential. The on-disc approach described here leverages the rapid print-cut-laminate (PCL) disc fabrication and prototyping method to create a permanent seal between disc materials and embedded nanoporous membranes. Rotational forces drive fluid flow, replacing capillary action, and complex pneumatic pumping systems. Adjacent microfluidic features form a flow path that directs fluid orthogonally (vertically) through these embedded membranes during assay execution. This method for membrane incorporation circumvents the need for solvents (e.g., acetone) to create the membrane-disc bond and sidesteps issues related to undesirable bypass flow. In other recently published work, we described an orthogonal flow (OF) platform that exploited embedded membranes for automation of enzyme-linked immunosorbent assays (ELISAs). Here, we more fully characterize flow patterns and cellulosic membrane behavior within the centrifugal orthogonal flow (cOF) format. Specifically, high-speed videography studies demonstrate that sample volume, membrane pore size, and ionic composition of the sample matrix significantly impact membrane behavior, and consequently fluid drainage profiles, especially when cellulosic membranes are used. Finally, prototype discs are used to demonstrate proof-of-principle for sandwich-type antigen capture and immunodetection within the cOF system. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

21. Development of an antigen detection assay for early point-of-care diagnosis of Zaire ebolavirus

Author

DeMers, Haley L., primary, He, Shihua, additional, Pandit, Sujata G., additional, Hannah, Emily E., additional, Zhang, Zirui, additional, Yan, Feihu, additional, Green, Heather R., additional, Reyes, Denise F., additional, Hau, Derrick, additional, McLarty, Megan E., additional, Altamura, Louis, additional, Taylor-Howell, Cheryl, additional, Gates-Hollingsworth, Marcellene A., additional, Qiu, Xiangguo, additional, and AuCoin, David P., additional

Published
2020
Full Text
View/download PDF

33. Large-Scale Evaluation of the Immuno-Mycologics Lateral Flow and Enzyme-Linked Immunoassays for Detection of Cryptococcal Antigen in Serum and Cerebrospinal Fluid

Author

Hansen, Jessica, Slechta, E. Susan, Gates-Hollingsworth, Marcellene A., Neary, Brandon, Barker, Adam P., Bauman, Sean, Kozel, Thomas R., and Hanson, Kimberly E.

Abstract

ABSTRACTCryptococcosis is a systemic infection caused by the pathogenic yeasts Cryptococcus neoformansand C. gattii. Detection of cryptococcal capsular antigen (CrAg) in serum and cerebrospinal fluid (CSF) plays an important diagnostic role. We prospectively compared the new Immuno-Mycologics Inc. (IMMY) lateral flow assay (LFA) and enzyme immunoassay (EIA) to our current CrAg test (Premier EIA; Meridian Bioscience Inc.). Discordant samples were retested with the latex-Cryptococcusantigen test (IMMY) and using serotype-specific monoclonal antibodies (MAbs). A total of 589 serum and 411 CSF specimens were tested in parallel. Qualitative agreement across assays was 97.7%. In all, 56 (41 serum and 15 CSF) samples were positive and 921 (527 serum and 394 CSF) samples were negative by all three assays. The 23 discrepant specimens were all Meridian EIA negative. Of 23 discordant specimens, 20 (87.0%) were positive by both the IMMY LFA and EIA, 2 were LFA positive only, and 1 was EIA positive only. Eleven discrepant specimens had adequate volume for latex agglutination (LA) testing; 8 were LA positive, and 3 were LA negative. LA-negative samples (2 CSF samples and 1 serum) had low IMMY LFA/EIA titers (=1:10). Serotype-specific MAb analysis of the LA-positive samples suggested that these specimens contained CrAg epitopes similar to those of serotype C strains. In conclusion, the IMMY assays showed excellent overall concordance with the Meridian EIA. Assay performance differences were related to issues of analytic sensitivity and possible serotype bias. Incomplete access to patient-level data combined with low specimen volumes limited our ability to fully resolve discrepant results.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results